Document is current
Any future updates will be listed below
-
Authors
Defachelles, A. S. https://orcid.org/0000-0002-4277-9871
Breunis, W. B.
Casanova, M.
Minard-Collin, V.
Hjadun, R.
Wasti, A.
Dávila Fajardo, R.
Terwisscha van Scheltinga, S.
Heenen, D.
Heinz, A. T.
Sparber-Sauer, M.
Merks, J. H. M.
Chisholm, J. C. https://orcid.org/0000-0003-3479-7997
Gatz, S. A. https://orcid.org/0000-0002-6438-9778
- License Information
-
More Information
Article History
Received: 1 April 2025
Revised: 11 June 2025
Accepted: 10 July 2025
First Online: 5 September 2025
Competing interests
: SAG has/has had an advisory role for EMD Serono/MERCK KGaA, AMGEN, and GILEAD; signed a consultancy agreement with AstraZeneca and Schroedinger Therapeutics; and received research funding from AstraZeneca (own grant and fee to institution), GSK (fee to institution), and BAYER (grant outside of this project). MC has/has had advisory roles AstraZeneca/Alexion, Roche; Merck, Servier; Speaker fee and travel expenses from Bayer. JHMM has/had advisory roles for MERCK, GSK, and BAYER. MSp had advisory roles for SOBI, Roche (hemophilia) and BAYER (hemophilia and funding outside this project). All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The other authors declare no competing interests.
: Not applicable.
: Not applicable.
